Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Items 201–300 of 769
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
Hofmann, I., Weiss, A., Elain, G., Schwaederle, M., Sterker, D., Romanet, V., Schmelzle, T., Lai, A., Brachmann, S. M., Bentires-Alj, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044146 · Cited by 69
“Expression of mutant K-RAS is known to be required for tumor maintenance in a genetically engineered mouse model of pancreatic cancer [6].”
BackgroundMehner, C., Miller, E. E., Khauv, D., Nassar, A., Oberg, A. L., Bamlet, W. R., Zhang, L., Waldmann, J., Radisky, E. S., Crawford, H. C., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0557-t · Cited by 76
“Activating mutations of KRAS are found in most pancreatic cancers (3), and expression of activated KRAS is necessary for initiation andmaintenance of pancreatic cancer in mouse models (42).”
BackgroundFunctional implication of Dclk1 and Dclk1-expressing cells in cancer
Westphalen, C. B., Quante, M., & Wang, T. C. (2016) · Small GTPases · doi:10.1080/21541248.2016.1208792 · Cited by 73
Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers
Rajbhandari, N., Lin, W.-C., Wehde, B. L., Triplett, A. A., & Wagner, K.-U. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.013 · Cited by 68
“In contrast to previous studies (Collins et al., 2012b; Ying et al., 2012), the upregulation of this oncogene in our model occurs in the absence of Dox (i.e., Tet-OFF system), and the downstream activation of MAP kinases can be swiftly repressed through administration of the ligand (Fig.”
BackgroundMethodResultInfluentialGenetics and Genetic Testing in Pancreatic Cancer
Whitcomb, D. C., Shelton, C. A., & Brand, R. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.057 · Cited by 75
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Liu, Z., Parveen, N., Rehman, U., Aziz, A., Sheikh, A., Abourehab, M. A. S., Guo, W., Huang, J., Wang, Z., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01696-5 · Cited by 75
“Combination or targeted therapies are more effective than conventional treatments because they block an important signalling pathway that is a key regulator of cell progression, metastasis, survival, and proliferation [89].”
BackgroundFalvo, D. J., Grimont, A., Zumbo, P., Fall, W. B., Yang, J. L., Osterhoudt, A., Pan, G., Rendeiro, A. F., Meng, Y., Wilkinson, J. E., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.11.008 · Cited by 69
Okada, M., Shibuya, K., Satō, A., Seino, S., Suzuki, S., Seino, M., & Kitanaka, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2087 · Cited by 72
“In these models, tumor regression caused by K-Ras inactivation was accompanied by extensive apoptosis of the tumor cells [47, 48], suggesting that K-Ras contributes to tumor maintenance at least in part through survival of bulk tumor cells.”
Genetics and Biology of Pancreatic Ductal Adenocarcinoma
Dunne, R. F., & Hezel, A. F. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.003 · Cited by 66
Targeting PIKfyve-driven lipid metabolism in pancreatic cancer
Cheng, C., Hu, J., Mannan, R., He, T., Bhattacharyya, R., Magnuson, B., Wisniewski, J. P., Peters, S., Karim, S. A., MacLean, D., et al. (2025) · Nature · doi:10.1038/s41586-025-08917-z · Cited by 87
Self-citationClassification, morphology and molecular pathology of premalignant lesions of the pancreas
Cooper, C. L., O'Toole, S. A., & Kench, J. G. (2013) · Pathology · doi:10.1097/pat.0b013e32835f2205 · Cited by 74
“Collins et al.(191) have demonstrated an important role for KRAS mutation, p53 loss and active Hedgehog signalling in the development and progression of PanIN lesions using a mouse”
BackgroundGüngör, C., Hofmann, B. T., Wolters‐Eisfeld, G., & Bockhorn, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12401 · Cited by 87
“Interestingly, oncogenic Kras is also required for the maintenance of PDAC in mice, suggesting that KRAS is not only required for the initiation of cancer (Collins et al., 2012).”
BackgroundJu, H., Li, H., Tian, T., Lu, Y., Bai, L., Chen, L.-Z., Sheng, H., Mo, H., Zeng, J., Deng, W., et al. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12285 · Cited by 69
Halbrook, C. J., Wen, H.-J., Ruggeri, J. M., Takeuchi, K. K., Zhang, Y., di Magliano, M. P., & Crawford, H. C. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.09.009 · Cited by 72
“Immunofluorescence was performed as previously described.(45) Immunohistochemistry slides were scanned on a Pannoramic SCAN slide scanner (Perkin Elmer, WA), and then annotation regions encompassing greater than 1 mm of tissue were processed by using appropriate algorithms for each stain quantified by using Halo softw…”
MethodSelf-citationZhang, Y., Yang, H., Du, Y., Liu, P., Zhang, J., Li, Y., Shen, H., Xing, L., Xue, X., Chen, J., et al. (2019) · Cancer Science · doi:10.1111/cas.14136 · Cited by 68
Self-citationType I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 78
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 100
“KRAS signalling is also known to alter the TME by promoting the development of the fibroinflammatory microenvironment necessary for PDAC cell survival 345 .”
Li, Q., Wang, H., Zogopoulos, G., Shao, Q., Dong, K., Lv, F., Nwilati, K., Gui, X.-Y., Cuggia, A., Liu, J.-L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12834 · Cited by 65
“The effects of additional mutations such as in Kras and TP53 transform ADM further into PanIN lesions and PDAC [43].”
BackgroundDeploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance
Beatty, G. L., Eghbali, S., & Kim, R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175232 · Cited by 64
Pramanik, S., Chen, Y., Song, H., Khutsishvili, I., Marky, L. A., Ray, S., Natarajan, A., Singh, P. K., & Bhakat, K. K. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac172 · Cited by 66
Liu, Y., Azizian, N. G., Sullivan, D. K., & Li, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-34890-6 · Cited by 79
Hu, C., Dadon, T., Chenna, V., Yabuuchi, S., Bannerji, R., Booher, R., Strack, P., Azad, N., Nelkin, B. D., & Maitra, A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0028 · Cited by 64
“We initially chose two highly characterized PDX models of PDAC, Panc253 and Panc265, from the JohnsHopkins PDAC BioBank (25).”
BackgroundInfluentialNeoplasms of the Exocrine Pancreas
Wolff, R. A., Crane, C. H., Li, D., Evans, D. B., Maitra, A., & Tsai, S. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094 · Cited by 64
Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
Liu, Y.-H., Hu, C., Hsu, Y.-S., & Lee, W. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05259-w · Cited by 77
Barceló, C., Etchin, J., Mansour, M. R., Sanda, T., Morell, M., Lobo, V. J. S.-A., Real, F. X., Capellá, G., Estanyol, J. M., Jaumot, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.041 · Cited by 68
Akhter, M. H., Madhav, N. S., & Ahmad, J. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1481863 · Cited by 63
Tirella, A., Kloc-Muniak, K., Good, L., Ridden, J., Ashford, M., Puri, S., & Tirelli, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.032 · Cited by 60
Donahue, K. L., Watkoske, H. R., Kadiyala, P., Du, W., Brown, K. L., Scales, M. K., Elhossiny, A. M., Espinoza, C. E., Opsahl, E. L. L., Griffith, B. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0100 · Cited by 64
“We also included matched “KRAS G12D OFF” groups for comparison at each timepoint (7, 12, 55).”
Self-citationOvercoming therapy resistance in pancreatic cancer: New insights and future directions
Espona‐Fiedler, M., Patthey, C., Lindblad, S., Sarró, I., & Öhlund, D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116492 · Cited by 71
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies
Matsuoka, T., & Yashiro, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.776 · Cited by 61
Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer
Grimont, A., Leach, S. D., & Chandwani, R. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.014 · Cited by 68
Maity, G., Haque, I., Ghosh, A., Dhar, G., Gupta, V. G., Sarkar, S., Azeem, I., McGregor, D. H., Choudhary, A., Campbell, D. R., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000333 · Cited by 67
“This study suggests the idea that inhibition of MAZ could be an anti-PDAC therapeutic avenue to achieve blockage or delay the progression of the deadly disease by overcoming K-Ras addition of pancreatic cancer cells (19, 71).”
BackgroundBoyer, S., Lee, H.-J., Steele, N., Zhang, L., Sajjakulnukit, P., Andren, A., Ward, M. H., Singh, R., Basrur, V., Zhang, Y., et al. (2022) · eLife · doi:10.7554/elife.73796 · Cited by 56
Self-citationMyeloid Cell Mediated Immune Suppression in Pancreatic Cancer
Kemp, S. B., Pasca di Magliano, M., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 55
miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells
Pham, H., Rodríguez, C., Donald, G. W., Hertzer, K. M., Jung, X., Chang, H.-H., Moro, A., Reber, H. A., Hines, O. J., & Eibl, G. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.042 · Cited by 57
Kumarasamy, V. M., Frangou, C. G., Wang, J., Wan, Y., Dynka, A., Rosenheck, H. R., Dey, P., Abel, E. V., Knudsen, E. S., & Witkiewicz, A. K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2504 · Cited by 63
Orlen, M., Vostrejs, W. P., Sor, R., McDevitt, J. C., Kemp, S. B., Kim, I., Kramer, A. B., Shifrin, N. T., Markosyan, N., Clendenin, C., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1475 · Cited by 70
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
“The discovery of activated KRAS oncogenes in human cancer cell lines in 1982 (9, 10), and their establishment as a sufficient (11) and necessary driver of PDAC growth (12–14), supported the potential significance of KRAS-targeted therapies for PDAC treatment.”
EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas
Hill, W., Ζαραγκούλιας, Α., Salvador-Barberó, B., Parfitt, G. J., Alatsatianos, M., Padilha, A., Porazinski, S. R., Woolley, T. E., Morton, J. P., Sansom, O. J., et al. (2021) · Current Biology · doi:10.1016/j.cub.2021.03.094 · Cited by 57
Multifaceted role for p53 in pancreatic cancer suppression
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211937120 · Cited by 55
“PanINs can be accompanied by extracellular matrix (ECM) remodeling (33, 34).”
BackgroundCRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
Lentsch, E., Li, L., Pfeffer, S., Ekici, A. B., Taher, L., Pilarsky, C. P., & Grützmann, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225706 · Cited by 61
“Mouse models have shown that an elevated frequency of activation in Kras leads to precursor lesions and the onset of PaCa [9,18,19].”
BackgroundDeregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer
Jin, X., Sun, Y., Yang, H., Ji, L., Yu, S., Chang, X., Lu, Z., & Chen, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125515 · Cited by 59
“Furthermore, previous studies indicated that KRAS and MAPK are required for the development of ADM and PanIN in mice [35, 36], and MAPK was found to be upregulated in pancreatitis [37].”
PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis
Jun, S., Lee, S., Kim, H.-C., Ng, C., Schneider, A. M., Ji, H. L., Ying, H., Wang, H., DePinho, R. A., & Park, J. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.026 · Cited by 75
“for the initiation but also for the maintenance of pancreatic cancer (Collins et al., 2012; Ying et al., 2012).”
BackgroundGu, D., Liu, H., Su, G. H., Zhang, X., Chin-Sinex, H., Hanenberg, H., Mendonca, M. S., Shannon, H. E., Chiorean, E. G., & Xie, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1030 · Cited by 55
“Activation of the Hh pathway has been reported in pancreatic cancer, but the exact role of this pathway in pancreatic tumorigenesis and progression remains largely unclear (9-15).”
BackgroundShen, J., Ha, D. P., Zhu, G., Rangel, D. F., Kobielak, A., Gill, P. S., Groshen, S. G., Dubeau, L., & Lee, A. S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616060114 · Cited by 59
“In addition to its role in tumor initiation, oncogenic KRAS is also required for PDAC maintenance (37).”
BackgroundMechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 68
Sivakumar, S., de Santiago, I., Chlon, L., & Markowetz, F. M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002223 · Cited by 53
Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice
Zhang, Y., Yan, W., Mathew, E., Kane, K. T., Brannon, A., Adoumie, M., Vinta, A., Crawford, H. C., & Pasca di Magliano, M. (2017) · eLife · doi:10.7554/elife.27388 · Cited by 52
Self-citationG4 DNA in ras genes and its potential in cancer therapy
Cogoi, S., & Xodo, L. E. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.02.002 · Cited by 57
Ferino, A., Rapozzi, V., & Xodo, L. E. (2020) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2019.111672 · Cited by 51
Mathew, E., Collins, M. A., Fernandez-Barrena, M. G., Holtz, A. M., Yan, W., Hogan, J. O., Tata, Z., Allen, B. L., Fernandez-Zapico, M. E., & Pasca di Magliano, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.556563 · Cited by 50
“Upon Kras inactivation, pERK1/2 levels decreased in the epithelium, and there was a transient increase in the stroma of iKras* pancreata, as described previously(17).”
BackgroundMethodInfluentialSelf-citationHuang, Y., Nahar, S., Nakagawa, A., Fernández‐Barrena, M. G., Mertz, J. A., Bryant, B. M., Adams, C. E., Mino-Kenudson, M. A., Alt, K. N. V., Chang, K. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2068 · Cited by 56
“Studies employing GEM models of PDAC have demonstrated the progressive appearance of a desmoplastic and pro-inflammatory stroma during the progression from PanIN to PDAC (28, 29).”
BackgroundA bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective
Pradhan, R., Krishnamurty, A. T., Fletcher, A. L., Turley, S. J., & Müller, S. (2021) · Immunological Reviews · doi:10.1111/imr.12990 · Cited by 53
Immunotherapy for Pancreatic Cancer: Present and Future
Aroldi, F., & Zaniboni, A. (2017) · Immunotherapy · doi:10.2217/imt-2016-0142 · Cited by 49
Metformin: review of epidemiology and mechanisms of action in pancreatic cancer
Eibl, G., & Rozengurt, E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09977-z · Cited by 55
Recent progresses of exosome–liposome fusions in drug delivery
Zheng, L., Hu, B., Zhao, D., Liu, W., Liu, Q., Huang, Y., & Ruan, S. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108647 · Cited by 53
The Role of nAChR and Calcium Signaling in Pancreatic Cancer Initiation and Progression
Schaal, C. M., Padmanabhan, J., & Chellappan, S. (2015) · Cancers · doi:10.3390/cancers7030845 · Cited by 55
“This occurs primarily through the formation of DNA adducts resulting in mutations in a number of vital genes implicated in tumorigenesis, including KRAS, which is mutated in nearly all pancreatic cancers [12–14].”
BackgroundEpithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & Pasca di Magliano, M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 49
Self-citationKim, S., Lahmy, R., Riha, C., Yang, C., Jakubison, B. L., van Niekerk, J., Staub, C., Wu, Y., Gates, K., Dong, D. S., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000328 · Cited by 48
Pancreatic Fibroblast Heterogeneity: From Development to Cancer
Garcia, P. E., Scales, M. K., Allen, B. L., & Pasca di Magliano, M. (2020) · Cells · doi:10.3390/cells9112464 · Cited by 48
“This fibroblast activation is dependent on oncogenic KRAS within the epithelium, and is reversed upon inactivation of oncogenic KRAS in a mouse model allowing inducible, reversible expression of oncogenic Kras in the pancreas [107].”
BackgroundAlmeida, P. P., Cardoso, C. P., & de Freitas, L. M. (2020) · BMC Cancer · doi:10.1186/s12885-020-6533-0 · Cited by 48
Principe, D. R., Xiong, R., Li, Y., Pham, T. D., Kamath, S. D., Dubrovskyi, O., Ratia, K. M., Huang, F., Zhao, J., Shen, Z., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116764119 · Cited by 49
“Oncogenic KRAS mutations have long been considered an early event in PDAC etiology, and sustained KRAS activity is required for both the initiation and maintenance of the neoplastic phenotype (45).”
State of the Art in Carbon Nanomaterials for Photoacoustic Imaging
Kang, M. S., Lee, H., Jeong, S. J., Eom, T. J., Kim, J., & Han, D. (2022) · Biomedicines · doi:10.3390/biomedicines10061374 · Cited by 52
“The KRas gene mutation is a commonly found mutation in pancreatic cancer that plays an important role in the growth and proliferation of cancer cells [116,117].”
BackgroundGenetic and molecular alterations in pancreatic cancer: Implications for personalized medicine
Chen, C. (2013) · Medical Science Monitor · doi:10.12659/msm.889636 · Cited by 51
“These mouse models have been well characterized and indicate that KrasG12D activates Hedgehog-mediated signaling and inflammatory pathways, and that it is essential for tumor maintenance [78].”
BackgroundGuo, J., Xie, K., & Zheng, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14995 · Cited by 65
“Of major importance to potential treatment of pancreatic cancer is that the oncoprotein KRAS is required for not only the initiation but also the maintenance of the disease in mice [76].”
BackgroundKameta, E., Sugimori, K., Kaneko, T., Ishii, T., Miwa, H., Sato, T. A., Ishii, Y., Sue, S., Sasaki, T., Yamashita, Y., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.5168 · Cited by 50
“Activating mutations in the KRAS gene are observed in >95% of patients with PDAC and may be one of the earliest steps in the formation of pancreatic intraepithelial neoplasia (PanIN) (9-11).”
Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview
Sikdar, N., Saha, G., Dutta, A., Ghosh, S., Shrikhande, S. V., & Banerjee, S. (2018) · Current Genomics · doi:10.2174/1389202919666180221160753 · Cited by 56
“Also, it was seen that sustained oncogenic Kras signaling is essential for growth and maintenance of metastasis in PDAC [131].”
BackgroundInfluentialCapturing cancer evolution using genetically engineered mouse models (GEMMs)
Hill, W., Caswell, D. R., & Swanton, C. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.003 · Cited by 49
Chu, P.-C., Yang, M.-C., Kulp, S. K., Salunke, S. B., Himmel, L. E., Fang, C.-S., Jadhav, A. M., Shan, Y.-S., Lee, C. T., Lai, M.-D., et al. (2015) · Oncogene · doi:10.1038/onc.2015.458 · Cited by 50
Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Chen, P.-Y., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A., del Rosario, A., Mertins, P., Qiao, J., Schafer, A. C., Gertler, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2129 · Cited by 46
“Recent in vivo studies aimed to characterize the requirement of sustained oncogenic Kras expression for pancreatic cancer maintenance have employed elegant mouse models engineered to express an inducible oncogenic Kras transgene (9,11,12).”
InfluentialTherapeutic potential of targeting the Wnt/β‐catenin pathway in the treatment of pancreatic cancer
Javadinia, S. A., Shahidsales, S., Fanipakdel, A., Joudi‐Mashhad, M., Mehramiz, M., Talebian, S., Maftouh, M., Mardani, R., Hassanian, S. M., Khazaei, M., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27835 · Cited by 49
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 51
“Importantly, in PDAC cells, oncogenic KRAS was shown to be responsible for activation of the Hh pathway, being required for the maintenance of the surrounding active stroma [84,85].”
BackgroundSingh, S. P., Dosch, A. R., Mehra, S., Silva, I. D. C., Bianchi, A., Garrido, V. T., Zhou, Z., Adams, A. M., Amirian, H., Box, E. W., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1200 · Cited by 50
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 56
Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer
Bhattacharyya, S., Oon, C. H., Kothari, A., Horton, W. R., Link, J. M., Sears, R. C., & Sherman, M. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191805 · Cited by 49
“Introduction The KRAS oncogene is mutated in >90% of pancreatic ductal adenocarcinoma (PDAC; Waters and Der, 2018), and oncogenic KRAS is critical for PDAC initiation and maintenance (Collins et al., 2012; Ying et al., 2012), making KRAS and its key effectors appealing targets for therapy.”
BackgroundPancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 65
“106,149 Further analysis showed reversion of PDAC following the removal of doxycycline in many mice.”
GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Baumgart, S., Chen, N., Zhang, J., Billadeau, D. D., Gaisina, I. N., Kozikowski, A. P., Singh, S. K., Fink, D., Ströbel, P., Klindt, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0309 · Cited by 53
“Pancreatic cancer exhibits a high therapeutic resistance against cytotoxic and apoptosis-inducing agents (39), and although genetic approaches targeting Kras in mice have shown encouraging results (40, 41), the oncogene is still deemed "undruggable" in mice and man.”
BackgroundFbxw7 Deletion Accelerates KrasG12D-Driven Pancreatic Tumorigenesis via Yap Accumulation
Zhang, Q., Zhang, Y., Parsels, J. D., Lohse, I., Lawrence, T. S., Pasca di Magliano, M., Sun, Y., & Morgan, M. A. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.009 · Cited by 44
“Immunohistochemistry and Immunoblotting Immunohistochemistry was conducted as previously described [3].”
MethodSelf-citationZhao, G., Ho, W., Chu, J., Xiong, X., Hu, B., Boakye‐Yiadom, K. O., Xu, X., & Zhang, X. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05007 · Cited by 45
Bhattacharyya, S., Oon, C. H., Diaz, L. F., Sandborg, H., Stempinski, E., Saoi, M., Morgan, T. K., López, C. S., Cross, J. R., & Sherman, M. H. (2024) · Nature Cancer · doi:10.1038/s43018-023-00703-y · Cited by 47
“…models have demonstrated that among the earliest responses to oncogenic KRAS activation or extinction in the pancreatic epithelium is the expansion or contraction, respectively, of this stromal reaction 46–48 , linking the core oncogenic circuitry driving pancreatic tumorigenesis to desmoplasia.”
Liu, Y., Han, J., Hsu, W., LaBella, K. A., Deng, P., Shang, X., de Lara, P. T., Cai, L., Jiang, S., & DePinho, R. A. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0489 · Cited by 47
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer
Veghini, L., Pasini, D., Fang, R., Delfino, P., Filippini, D., Neander, C., Vicentini, C., Fiorini, E., Lupo, F., D’Agosto, S. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54975-8 · Cited by 53
“Activating mutations of KRAS are nearly universal in PDAC 24 and result in the hyperactivation of the RAS/MEK/ERK (Mitogen-activated protein kinase, MAPK) pathway, which plays a central role in tumour initiation and maintenance 25,26 .”
NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation
Heßmann, E., Zhang, J., Chen, N., Hasselluhn, M. C., Liou, G., Störz, P., Ellenrieder, V., Billadeau, D. D., & König, A. O. (2015) · Stem Cells International · doi:10.1155/2016/5272498 · Cited by 46
“instead promotes a transition frommetaplastic cells to PanIN precursor lesions that eventually progress to invasive PDAC [10, 11].”
Chu, N. J., Armstrong, T. D., & Jaffee, E. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1186 · Cited by 43
“Early mutant Kras-driven neoplastic cells secrete cytokines, IL8, IL6, and granulocyte macrophage colony-stimulating factor (GM-CSF), which recruits Tregs and MDSCs to the TME (10, 24, 35, 36).”
InfluentialCellular and molecular aspects of pancreatic cancer
Gharibi, A., Adamian, Y., & Kelber, J. A. (2016) · Acta Histochemica · doi:10.1016/j.acthis.2016.01.009 · Cited by 52
“It has been shown that oncogenic KRas not only initiates PDAC, but is also necessary for tumor progression and maintenance (Collins et al., 2012a; Hingorani et al., 2003; Ying et al., 2012) as well as growth of metastatic lesions (Collins et al., 2012b).”
BackgroundAlonso, S., Hernandez, D., Chang, Y., Gocke, C., McCray, M. E., Varadhan, R., Matsui, W. H., Jones, R. J., & Ghiaur, G. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88152 · Cited by 45
Cho, Y.-R., Lee, J. H., Kim, J. H., Lee, S., Yoo, S., Jung, M., Kim, S. J., Yoo, H. J., Pack, C.-G., Rho, J. K., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12324 · Cited by 44
“(Collins et al., 2012; Son et al., 2013; Ying et al., 2012) Thus, it was believed that KRAS is an ideal therapeutic target; however, the biochemical properties of this gene make it pharmacologically difficult to inhibit, and attempts to block essential post-translational modifications of KRAS have…”
BackgroundSesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer
Laurella, L. C., Mirakian, N. T., Garcia, M. N., Grasso, D., Sülsen, V. P., & Papademetrio, D. L. (2022) · Molecules · doi:10.3390/molecules27113492 · Cited by 43
“Moreover, several studies report that PDAC is highly dependent on this oncogene for tumor initiation and maintenance [27,28].”
BackgroundA MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
Ischenko, I., Petrenko, O., & Hayman, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4538 · Cited by 43
“Genetically engineered mouse models of PDAC have demonstrated that continuous KRAS signaling is required for both progression and maintenance of PDAC [36-38].”
Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked
Evan, G. I., Hah, N., Littlewood, T. D., Sodir, N. M., Campos, T., Downes, M., & Evans, R. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3275 · Cited by 45
An Emerging Role for the Unfolded Protein Response in Pancreatic Cancer
Robinson, C. M., Talty, A., Logue, S. E., Mnich, K., Gorman, A. M., & Samali, A. (2021) · Cancers · doi:10.3390/cancers13020261 · Cited by 46
“These mutations arise early in disease and promote tumorigenesis [9].”
BackgroundCXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer
Purohit, A., Varney, M. L., Rachagani, S., Ouellette, M. M., Batra, S. K., & Singh, R. K. (2016) · Oncotarget · doi:10.18632/oncotarget.6906 · Cited by 46
“While recent reports in PDAC have identified the KRAS-CXC chemokine axis, it remains unclear if this signaling can serve as an early biomarker for PDAC progression as KRAS mutations are required for both initiation and maintenance of PDAC [31].”
BackgroundChallenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis
Qiu, W., & Su, G. H. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9408-2 · Cited by 50
Frank, K. J., Mulero-Sánchez, A., Berninger, A., Ruiz-Cañas, L., Bosma, A., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100815 · Cited by 40
Guo, K., Ren, S., Zhang, H., Cao, Y., Zhao, Y., Wang, Y., Qiu, W., Tian, Y., Song, L., & Wang, Z. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c00865 · Cited by 44
Husain, K. M., Centeno, B. A., Chen, D.-T., Fulp, W. J., Perez, M. C., Lee, G., Luetteke, N., Hingorani, S. R., Sebti, S. M., & Malafa, M. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt002 · Cited by 40
“uk/genetics/CGP/cosmic/), and mutant Kras has been shown to be required for the initiation and maintenance of pancreatic cancer in animal models (9,10).”
BackgroundProgress in the application of exosomes as therapeutic vectors in tumor-targeted therapy
Xie, X., Wu, H., Li, M., Chen, X., Xiao-yun, X., Ni, W., Lu, C., Ni, R., Bao, B., & Xiao, M. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.01.001 · Cited by 41
Pancreatic Cancer from Molecular Pathways to Treatment Opinion
Karanikas, M., Esempidis, A., Chasan, Z. T. M., Deftereou, T.-E., Antonopoulou, M. I., Bozali, F., Amarantidis, K., & Man, Y.-G. (2016) · Journal of Cancer · doi:10.7150/jca.15419 · Cited by 47
“[45] Overexpressed MAPK through the active form of RAF results in PanIN/pancreatic ductal adenocarcinoma formation;and the silencing of MAPK signaling inhibits tumor initiation.[46, 47] Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling is another important pathway that has been studied in pancreatic canc…”
BackgroundEpithelial Notch signaling is a limiting step for pancreatic carcinogenesis
Thomas, M. M., Zhang, Y., Mathew, E., Kane, K. T., Maillard, I. P., & di Magliano, M. P. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-862 · Cited by 41
“Several studies have reported that, in mice, the induction of acute pancreatitis synergizes with oncogenic Kras to induce rapid and extensive PanIN formation [6,24,37-39].”
BackgroundInfluentialSelf-citationPathology, genetics and precursors of human and experimental pancreatic neoplasms: An update
Esposito, I., Segler, A., Steiger, K., & Klöppel, G. (2015) · Pancreatology · doi:10.1016/j.pan.2015.08.007 · Cited by 40
“On the molecular level, some limitations of GEMM have been overcome in the last years (for example by using inducible models [104]), but some still remain (such as expression of mutant allels within the whole organ/cell type and not only in a single cell).”
Background
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.